Analysts Set Delcath Systems, Inc. (NASDAQ:DCTH) PT at $22.50

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) have been assigned an average rating of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $22.50.

DCTH has been the subject of a number of recent research reports. Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings upgraded Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, May 11th. BTIG Research reduced their price objective on Delcath Systems from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Evercore set a $27.00 price objective on Delcath Systems in a research note on Thursday, February 26th. Finally, Zacks Research lowered Delcath Systems from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th.

Hedge Funds Weigh In On Delcath Systems

Institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System purchased a new position in shares of Delcath Systems during the 2nd quarter valued at about $26,000. Russell Investments Group Ltd. purchased a new position in shares of Delcath Systems during the 3rd quarter valued at about $29,000. Tower Research Capital LLC TRC acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at about $40,000. Legal & General Group Plc acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Delcath Systems during the 2nd quarter valued at about $151,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

Shares of DCTH opened at $11.02 on Friday. The stock has a 50-day moving average of $10.31 and a two-hundred day moving average of $9.89. Delcath Systems has a one year low of $8.12 and a one year high of $17.35. The stock has a market cap of $380.41 million, a P/E ratio of 1,102.00 and a beta of 0.54.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.07. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%.The company had revenue of $24.99 million during the quarter, compared to analysts’ expectations of $23.51 million. Analysts predict that Delcath Systems will post -0.88 EPS for the current fiscal year.

Delcath Systems Company Profile

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.